Hematology and Blood Disorders

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Editorial - Hematology and Blood Disorders (2025) Volume 8, Issue 2

Platelets at War: ITP and the Autoimmune Battle Against Clotting

Jecko Thachil *

Department of Medicine, Yale University, New Haven, United States

*Corresponding Author:
Jecko Thachil
Department of Medicine,
Yale University, New Haven, United States
E-mail: jecko.thachil@mft.nhs.uk

Received: 01-Aug-2025, Manuscript No. AAHBD-24-171322; Editor assigned: 03-Aug-2025, PreQC No. AAHBD-24-171322(PQ);Reviewed:16-Aug-2025, QC No. AAHBD-24-171322; Revised:18-Aug-2025, Manuscript No. AAHBD-24-171322(R); Published: 24-Aug-2025, DOI:10.35841/AAHBD-8.2.225

Citation: Thachil J. Platelets at war: ITP and the autoimmune battle against clotting. Hematol Blood Disord. 2025;8(2):225

Visit for more related articles at Hematology and Blood Disorders

Introduction

In the intricate battlefield of the human immune system, not all wars are fought against foreign invaders. Sometimes, the body turns on itself, mistaking its own cells for enemies. One such internal conflict unfolds in Immune Thrombocytopenic Purpura (ITP)—a disorder where the immune system targets platelets, the tiny cell fragments responsible for blood clotting. This autoimmune assault can lead to excessive bleeding, bruising, and in severe cases, life-threatening hemorrhages. Immune Thrombocytopenic Purpura (also known as Idiopathic Thrombocytopenic Purpura) is an autoimmune condition characterized by a low platelet count (thrombocytopenia) due to the immune system mistakenly attacking and destroying platelets. Platelets are essential for blood clotting, and their depletion can result in spontaneous bleeding or difficulty stopping bleeding after injury [1].

Support groups, counseling, and patient education are vital components of comprehensive care. Empowering patients to understand their condition fosters resilience and informed decision-making. Research into ITP continues to evolve, with promising developments in: Biomarkers for early diagnosis and treatment response, Targeted therapies that modulate specific immune pathways, Gene expression profiling to understand individual disease patterns. Clinical trials are exploring novel agents that offer better efficacy with fewer side effects. Personalized medicine may soon allow tailored treatment plans based on genetic and immunologic profiles. ITP can be acute (typically in children and resolving within six months) or chronic (more common in adults and lasting longer than six months). The exact cause remains unclear, but it often follows viral infections, vaccinations, or autoimmune triggers. The hallmark of ITP is bleeding, which may manifest as: Petechiae (tiny red or purple spots on the skin), Easy bruising, Nosebleeds, Bleeding gums, Heavy menstrual bleeding, Blood in urine or stool [2].

Despite these symptoms, many individuals with ITP feel otherwise healthy, making diagnosis challenging without routine blood tests. ITP is a diagnosis of exclusion, meaning other causes of thrombocytopenia must be ruled out first. Diagnostic steps include: Reveals low platelet count. Assesses platelet morphology and rules out other hematologic disorders. Occasionally performed to exclude malignancies or marrow failure. Tests for lupus, HIV, hepatitis C, and other conditions that may mimic or trigger ITP [3].

There is no single definitive test for ITP, which makes clinical judgment and patient history vital in diagnosis. In ITP, autoantibodies—proteins produced by the immune system—target platelets for destruction. These antibodies bind to platelet surface antigens, marking them for removal by the spleen. Additionally, impaired platelet production in the bone marrow may contribute to the low count. This immune misfire is often triggered by viral infections (e.g., Epstein-Barr virus, cytomegalovirus), vaccinations, or autoimmune diseases like lupus. In children, ITP frequently follows a viral illness and resolves spontaneously. In adults, it tends to be chronic and more resistant to treatment. Treatment depends on the severity of symptoms and platelet count. Not all cases require intervention—some patients are monitored without medication if bleeding is minimal [4].

Corticosteroids (e.g., prednisone): Suppress the immune response and increase platelet count. Intravenous immunoglobulin (IVIG): Temporarily blocks platelet destruction. Anti-D immunoglobulin: Used in Rh-positive patients to reduce splenic platelet clearance. A monoclonal antibody that targets B cells producing autoantibodies. Thrombopoietin receptor agonists (e.g., eltrombopag, romiplostim): Stimulate platelet production. Surgical removal of the spleen, which is responsible for platelet destruction. Treatment goals focus on preventing bleeding rather than normalizing platelet counts. Long-term remission is possible, but relapses are common [5].

Conclusion

ITP often follows a viral infection and resolves within weeks or months. Treatment is usually conservative. Chronic ITP is more common, with fluctuating platelet levels and a greater need for ongoing therapy. Pregnancy poses unique challenges, as ITP can affect both the mother and fetus. Close monitoring and tailored treatment are essential to ensure safe delivery. ITP affects approximately 3 to 4 per 100,000 adults annually, with a slightly higher incidence in women. In children, the incidence is about 5 per 100,000, with most cases resolving spontaneously. Despite its rarity, ITP can have a profound impact on quality of life. Patients often live with uncertainty, fearing spontaneous bleeding or side effects from treatment. Advocacy organizations like the Platelet Disorder Support Association (PDSA) provide resources, education, and community support. Living with ITP involves more than managing physical symptoms. The unpredictability of platelet counts and bleeding episodes can lead to anxiety, depression, and social withdrawal. Patients may avoid sports, travel, or even routine dental procedures due to bleeding risks.

References

  1. Gatta G, Botta L, Rossi S et al.Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—A population-based study.Lancet Oncol. 2014;15(1):35-47.

    2. Indexed at, Google ScholarCross Ref

  2. Hudson MM, Ness KK, Gurney JG et al.Clinical ascertainment of health outcomes among adults treated for childhood cancer JAMA. 2013; 309(22):2371-81.

    3. Indexed at, Google Scholar,Cross Ref

  3. Morley JE, Vellas B, Van Kan GA et al.Frailtyconsensus: A call to action.Am J Med. 2013;14(6):392-7.

    4. Indexed at, Google Scholar,Cross Ref

  4. Van Iersel L, Li Z, Srivastava DK et al.Hypothalamic-pituitary disorders in childhood cancer survivors: Prevalence, risk factors and long-term health outcomesJ Clin Endocr. 2019;104(12):6101-15.

    5. Indexed at, Google Scholar,Cross Ref

  5. Aaronson NK, Muller M, Cohen PD et al.Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations.J Clin Epidemiol. 1998;51(11):1055-68.

    6. Indexed at, Google Scholar,Cross Ref

Get the App